中医药治疗症状性颅内动脉粥样硬化性狭窄研究进展
Progress in the Study of Chinese Medicine for Symptomatic Intracranial Atherosclerotic Stenosis
DOI: 10.12677/TCM.2023.129392, PDF,   
作者: 邓鑫敏*, 常 文, 吕小锋, 来 锐：成都中医药大学临床医学院，四川 成都；梁静涛#：成都中医药大学附属医院神经内科，四川 成都
关键词: 症状性颅内动脉狭窄；中医药；综述；Symptomatic Intracranial Artery Stenosis； Traditional Chinese Medicine； Review
摘要: 症状性颅内动脉粥样硬化性狭窄是临床中导致缺血性脑血管疾病发生最常见的原因之一，颅内动脉狭窄的存在使患者脑血管缺血事件复发率明显增高，严重影响患者的预后，降低了患者生活质量，增加了社会负担。西医目前以抗血小板聚集、调脂稳斑及血管内治疗为主，但疗效欠佳且缺血事件复发率较高。中医药从整体观念出发，讲求辨证论治，近年来对症状性颅内动脉狭窄的治疗显示出一定优势。本文就近10年来中医药治疗症状性颅内动脉狭窄相关研究做一综述，以期为临床治疗提供参考。
Abstract: Symptomatic intracranial atherosclerotic stenosis is one of the most common causes of ischemic cerebrovascular disease in clinical practice. The presence of intracranial arterial stenosis significantly increases the recurrence rate of cerebrovascular ischemic events, seriously affects the prognosis of patients, reduces their quality of life, and increases the social burden. Western medicine currently focuses on antiplatelet aggregation, stabilizing plaques through lipid regulation, and endovascular treatment, but the therapeutic effect is unsatisfactory and the recurrence rate of ischemic events is high. Traditional Chinese Medicine (TCM) takes a holistic approach and emphasizes individualized treatment based on syndrome differentiation. In recent years, TCM has shown certain advantages in the treatment of symptomatic intracranial arterial stenosis. This article provides a review of the relevant research on TCM treatment of symptomatic intracranial arterial stenosis in the past decade, with the aim of providing reference for clinical treatment.
文章引用：邓鑫敏, 常文, 吕小锋, 来锐, 梁静涛. 中医药治疗症状性颅内动脉粥样硬化性狭窄研究进展[J]. 中医学, 2023, 12(9): 2613-2618. https://doi.org/10.12677/TCM.2023.129392

参考文献

[1] 董强, 黄家星, 黄一宁, 等. 症状性动脉粥样硬化性颅内动脉狭窄中国专家共识[J]. 中国神经精神疾病杂志, 2012, 38(3): 129-145.
[2] Wang, Y., Zhao, X., Liu, L., et al. (2014) Prevalence and Outcomes of Symptomatic Intracranial Large Artery Stenoses and Occlusions in China: The Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke, 45, 663-669. [Google Scholar] [CrossRef] 
[3] Zaidat, O.O., Fitzsimmons, B., Woodward, B.K., et al. (2015) Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients with Symptomatic Intracranial Stenosis. JAMA, 313, 1240-1248. [Google Scholar] [CrossRef] [PubMed]
[4] Chimowitz, M.I., Lynn, M.J., Derdeyn, C.P., et al. (2011) Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis. The New England Journal of Medicine, 365, 993-1003. [Google Scholar] [CrossRef] 
[5] Kleindorfer, D.O., Towfighi, A., Chaturvedi, S., et al. (2021) 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline from the American Heart Association/American Stroke Association. Stroke, 52, e364-e467. [Google Scholar] [CrossRef] 
[6] 李澎涛, 王永炎, 黄启福. “毒损脑络”病机假说的形成及其理论与实践意义[J]. 北京中医药大学学报, 2001(1): 1-6+16.
[7] 陈小敏, 张健, 丁砚兵, 等. 从络虚毒损探讨症状性颅内动脉粥样硬化性狭窄因机治法[J]. 北京中医药大学学报, 2022, 45(2): 135-139.
[8] 梁风俊, 杜菊梅, 张磊, 等. 温脉活血化瘀方联合血管介入治疗对颅内前循环动脉狭窄病人再狭窄及脑血流动力学的影响[J]. 中西医结合心脑血管病杂志, 2021, 19(3): 402-406.
[9] 王晓静, 卢波, 吕志坤, 等. 匹伐他汀联合化痰通络汤治疗症状性颅内动脉狭窄的效果及机制探讨[J]. 山东医药, 2020, 60(29): 70-72.
[10] 王斌, 翁卿吉, 纪仁浩, 等. CT联合血清指标评价脑梗死患者颈动脉粥样硬化的临床价值[J]. 中华老年心脑血管病杂志, 2018, 20(6): 580-584.
[11] 袁山旗, 赵红敏, 王晓叶, 等. 颈动脉超声联合血管内皮生长因子、基质金属蛋白酶-9、超敏C反应蛋白检测在动脉粥样硬化斑块稳定性中的应用分析[J]. 实用临床医药杂志, 2019, 23(17): 27-29, 33.
[12] 曹盼盼. 通脑饮治疗颅内动脉狭窄、CYP2C19基因突变的急性脑梗死临床研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2018.
[13] 侯斌, 张树泉, 杨静静, 等. 益肾通脉方对症状性颅内动脉重度狭窄伴CYP2C19基因变异的急性脑梗死干预研究[Z]. 2018.
[14] 吴鹏, 吴云虎. 血府逐瘀汤对症状性颅内动脉狭窄患者生化指标及预后的影响[J]. 现代医学与健康研究电子杂志, 2022, 6(23): 95-98.
[15] 贾洪亮, 阮海晶, 薛静静. 桃红四物汤加味治疗颈内动脉狭窄所致缺血性眼病19例[J]. 江西中医药大学学报, 2015, 27(1): 38-39, 42.
[16] 孙桂阳. 益气化痰通络方对气虚痰瘀型sICAS效应机制的研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2021.
[17] 黄年平, 向建军, 黄信全, 等. 降脂活血片联合瑞舒伐他汀钙片治疗症状性颅内动脉粥样硬化性狭窄的疗效观察[J]. 中西医结合心脑血管病杂志, 2020, 18(6): 976-979.
[18] 秦劭晨, 王爱梅, 马阮昕, 等. 补阳还五汤胶囊制剂对症状性颅内大动脉狭窄患者脑血流储备的影响[J]. 长春中医药大学学报, 2018, 34(3): 508-511.
[19] 王球. 脑梗死复发与血清超敏C反应蛋白的相关性分析[J]. 中国全科医学, 2009, 12(8): 653-654.
[20] 张敬伟. NO, SOD与缺血性脑血管病的关系[J]. 中国误诊学杂志, 2005(5): 900.
[21] 汪秀丽, 陈小奇, 孙国兵, 等. 丹红注射液治疗症状性颅内动脉粥样硬化性狭窄的疗效观察[J]. 神经损伤与功能重建, 2016, 11(6): 567-568.
[22] 朱清, 杜雯雯, 姚蓓蓓, 等. 银杏二萜内酯葡胺注射液治疗伴有颅内动脉狭窄的急性部分前循环脑梗死的临床疗效观察[J]. 北京中医药, 2020, 39(11): 1140-1142, 1146.